Mediar
is a Massachusetts-based biotechnology company that researches and develops antibody therapeutics for the treatment of halt fibrosis... Read moreMediar
is a Massachusetts-based biotechnology company that researches and develops antibody therapeutics for the treatment of halt fibrosis... Read more
News
Jun 09, 2025
Pharmabiz
Mediar: Mediar Therapeutics doses first patient in phase 2 WISPer trial of MTX463 for idiopathic pulmonary fibrosis
Jan 15, 2025
Global Legal Chronicle
Mediar: Mediar Therapeutics' Global Licensing Agreement with Lilly
Jan 10, 2025
Endpoints News
Mediar: Lilly ventures into pulmonary fibrosis with startup Mediar
Aug 08, 2024
Clinical Trials Arena
Mediar: Mediar doses first patient in Phase I trial of MTX-474 for fibrosis treatment
Aug 07, 2024
PR Newswire
Press Release: Mediar : Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis
May 07, 2024
Pharmabiz
Mediar: Mediar begins patient dosing in US FDA approved phase 1 trial of MTX463
Oct 25, 2023
Marketscreener
Mediar: Gimv : Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition
Mar 15, 2023
BioPharma Dive
Mediar: With focus on fibrosis, startup Mediar draws big pharma backing
Mar 15, 2023
European Biotechnology
Mediar Therapeutics: European VCs join US$105m financing of US Mediar Thx
Mar 15, 2023
FinSMEs
Mediar Therapeutics: Mediar Therapeutics Raises $105M in Funding
